Angie You - 04 Aug 2026 Form 3 Insider Report for Attovia Therapeutics, Inc. (ATTO)

Reporting relationship: Director
Issuer ticker: ATTO
Reported as of: 04 Aug 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 04 Aug 2026, 19:38:54 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven Chan, Attorney-in-Fact

Key filing fact

Angie You filed Form 3 for Attovia Therapeutics, Inc. (ATTO) on 04 Aug 2026.

Key facts

This page summarizes Angie You's Form 3 filing for Attovia Therapeutics, Inc. (ATTO).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 19:38.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647664 Primary reporting owner

You Angie

Relationship: Director
Address: C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS
Signature: /s/ Steven Chan, Attorney-in-Fact
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATTO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 52,852
Date: 04 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATTO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 04 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,913
Exercise price: $4.92
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option vests over a three-year period. The vesting schedule is as follows: 33% vested on June 29, 2025, an additional 33% vested on June 29, 2026, and the final 33% shall vest on July 29, 2027, subject to reporting person's continued service to the Issuer on each vesting date.

Footnote F2

The option vests over a three-year period. The vesting schedule is as follows: 33% vested on May 18, 2026, an additional 33% shall vest on May 18, 2027, and the final 33% shall vest on May 18, 2028, subject to the reporting person's continued service to the Issuer on each vesting date.

SEC remarks

Exhibit 24.1